title: [Efficacy and safety of sulbactam/cefoperazone for hepato-biliary infections].
abstract: We studied efficacy and safety of sulbactam/cefoperazone (SBT/CPT) in the treatment of biliary tract infections in hospitalized patients at 26 hospitals from February 1993 to March 1995. Secondary to dropout, 273 out of 338 patients entered in the study were evaluated, 127 patients with cholecystitis, 132 patients with cholangitis, and 14 patients with liver abscesses. Of these, 93 patients (34.1% had malignancy as an underlying disease. SBT/CPZ had an efficacy of 79.9% (218 patients; excellent: 52, good: 166), with the efficacy in patients with cholecystitis, cholangitis and liver abscess at 89.0% (113 patients), 77.3% (102 patients and 21.4% (3 patients), respectively. A significant difference (p < 0.05) was observed in the efficacy rates of patients with (59 patients [63.4%]) and without malignancy (159 patients [88.3%]). A total of 84 strains were isolated from bile specimens of 53 patients, and the major isolates were Escherichia coli, Pseudomonas aeruginosa and Enterococcus spp. Two or more bacterial strains were isolated simultaneously in 20 patients. Mild or moderate side effect (allergic reaction including rash etc.) were noted in 4 patients (1.18%), and laboratory abnormalities (increased GOT, etc.) were in 16 patients (4.71%) out of the total 338 patients. This study clearly demonstrated that SBT/CPZ retains its excellent clinical efficacy and safety profile, throughout its use over the past decade.
authors.affiliation: Department of Surgery, Nagoyashi Koseiin Geriatic Hospital.
authors.forename: N
authors.initials: N
authors.lastname: Shinagawa
authors.forename: S
authors.initials: S
authors.lastname: Takeda
authors.forename: S
authors.initials: S
authors.lastname: Oohira
authors.forename: Y
authors.initials: Y
authors.lastname: Yasuda
authors.forename: M
authors.initials: M
authors.lastname: Fujisaki
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Mitamura
authors.forename: T
authors.initials: T
authors.lastname: Nishio
authors.forename: M
authors.initials: M
authors.lastname: Itakura
authors.forename: M
authors.initials: M
authors.lastname: Koyama
authors.forename: M
authors.initials: M
authors.lastname: Hirano
authors.forename: R
authors.initials: R
authors.lastname: Ohyama
authors.forename: M
authors.initials: M
authors.lastname: Kako
authors.forename: Y
authors.initials: Y
authors.lastname: Amako
authors.forename: K
authors.initials: K
authors.lastname: Okuda
authors.forename: T
authors.initials: T
authors.lastname: Iwasa
authors.forename: A
authors.initials: A
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Hirano
authors.forename: S
authors.initials: S
authors.lastname: Takashima
authors.forename: N
authors.initials: N
authors.lastname: Ohswawa
authors.forename: S
authors.initials: S
authors.lastname: Nakaya
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: F
authors.initials: F
authors.lastname: Zeze
authors.forename: J
authors.initials: J
authors.lastname: Ishii
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002438:Cefoperazone / Q000008:administration & dosage* / Q000009:adverse effects; D002761:Cholangitis / Q000188:drug therapy*; D002764:Cholecystitis / Q000188:drug therapy*; D004338:Drug Combinations; D016983:Enterococcus; D005260:Female; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D008100:Liver Abscess / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D011552:Pseudomonas Infections / Q000188:drug therapy; D013407:Sulbactam / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D002438:Cefoperazone; C057923:sulperazone; D013407:Sulbactam